Welcome to our dedicated page for Well Health Tech news (Ticker: WHTCF), a resource for investors and traders seeking the latest updates and insights on Well Health Tech stock.
WELL Health Technologies Corp. (WHTCF) is a leader in digital healthcare innovation, providing AI-driven solutions that empower providers and modernize patient care. This news hub offers investors and industry professionals a centralized source for tracking the company’s latest developments.
Access timely updates on earnings reports, strategic partnerships, product enhancements, and regulatory milestones. Our curated collection ensures you stay informed about WHTCF’s role in advancing interoperable EMR systems, clinic management tools, and AI-powered healthcare technologies.
Explore press releases covering acquisitions, operational expansions, and technological breakthroughs that strengthen WELL Health’s position across North American markets. Each update is organized to highlight impacts on healthcare delivery efficiency and long-term growth potential.
Bookmark this page for streamlined access to WHTCF’s evolving initiatives in digital health transformation. Check back regularly for authoritative reporting on how the company continues to reshape provider workflows through secure, scalable solutions.
WELL Health Technologies (TSX: WELL, OTCQX: WHTCF) has received approval from the Toronto Stock Exchange for its renewed Normal Course Issuer Bid (NCIB). The program allows WELL to repurchase up to 6,326,417 shares, representing 2.5% of its outstanding shares, over a 12-month period from May 20, 2025 to May 19, 2026.
Daily purchases on the TSX will be limited to 284,830 shares. Under the previous 2024 NCIB, WELL purchased 298,500 shares at an average price of $4.91. The company's limited buyback activity was due to their previous broker Eight Capital winding down operations and funds being allocated to alternative opportunities.
WELLSTAR Technologies, a subsidiary of WELL Health Technologies (TSX:WELL, OTCQX:WHTCF), has launched Nexus AI, a Canadian-built artificial intelligence platform for healthcare providers. The platform features advanced ambient scribe capabilities and integrates with Canadian EMR systems to streamline clinical workflows and reduce administrative burden.
Developed by physicians and AI researchers from the University of Toronto and HEALWELL AI, Nexus AI is already being used by thousands of providers across 20 specialties in Canada. The platform will expand to include disease detection, medical coding, billing automation, and clinical decision support features. Notably, Nexus AI is participating in Canada Health Infoway's AI Scribe Program, which will fund one-year licenses for up to 10,000 eligible primary care clinicians.
WELL Health Technologies (TSX: WELL, OTCQX: WHTCF) has scheduled the release of its Fourth Quarter and Year End 2024 financial results on April 14, 2025, after market close. The digital healthcare company will host a conference call and webcast to discuss the results on April 15, 2025, at 1:00 PM ET (10:00 AM PT).
The earnings call will be led by Chairman and CEO Hamed Shahbazi and CFO Eva Fong. Participants can join through various dial-in options, including local Toronto (437-900-0527), Vancouver (604-259-0841), North American toll-free (1-888-510-2154), and international lines.
WELL Health Technologies (TSX: WELL, OTCQX: WHTCF) has received a Management Cease Trade Order (MCTO) from the British Columbia Securities Commission following a delay in filing its Annual Filings for the year ended December 31, 2024. The MCTO restricts the CEO and CFO from trading company securities until the required documents are filed.
The Annual Filings include the company's annual information form, audited annual financial statements, and management's discussion and analysis. During this period, the company has committed not to issue or acquire securities from insiders or employees. The MCTO does not affect non-insider shareholders' ability to trade.
The company will provide bi-weekly default status reports and announce completion once the Annual Filings are submitted to SEDAR+.
WELL Health Technologies Corp. (WHTCF) has exercised its call option rights to acquire significant shares in HEALWELL AI Inc. The transaction occurred concurrent with HEALWELL's acquisition of Orion Health Holdings for approximately NZ$175 million on April 1, 2025.
Through the exercise of the Call Right, WELL acquired 30.8 million Subordinate Voting Shares and 30.8 million Multiple Voting Shares from HEALWELL's founding shareholders. Following the transaction, WELL now owns 97,473,161 HEALWELL Shares and 30,800,000 Multiple Voting Shares, representing approximately 37% of the economic interest and 69% of the voting rights in HEALWELL on a partially-diluted basis.
WELL Health Technologies Corp. (WHTCF) has announced its intention to exercise a call option to acquire shares in HEALWELL AI Inc. concurrent with HEALWELL's acquisition of Orion Health Holdings The call option allows WELL to purchase up to 30.8 million Subordinate Voting Shares and 30.8 million Multiple Voting Shares from HEALWELL's founding shareholders at $0.125 and $0.0001 per share respectively.
HEALWELL is set to acquire Orion Health for approximately NZ$175 million, with closing anticipated on April 1, 2025. Following the exercise of the call right and the Orion Health acquisition, WELL is expected to own approximately 37% of the economic interest and 69% of the voting rights in HEALWELL on a partially-diluted basis. WELL was previously approved as a control person of HEALWELL by shareholders and the Toronto Stock Exchange.
WELL Health Technologies (TSX: WELL, OTCQX: WHTCF) has reported record patient visits for fiscal year 2024, achieving 5.7 million total patient visits, representing a significant 32% year-over-year growth, with organic growth accounting for 30%.
The company's Canadian patient services business demonstrated exceptional performance, recording 3.125 million patient visits, marking a 35% year-over-year increase. The organic growth in Canadian operations was particularly strong at 32%, comprised of 26% same clinic sales growth and 6% absorption growth.
These preliminary operational results highlight WELL's success in leveraging its technology-enabled care model to drive strong organic growth across its enterprise, particularly in its Canadian Clinics division.